Results 171 to 180 of about 23,604 (308)

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory   +13 more
wiley   +1 more source

Identifying Factors Associated with the Difference between Sidama Development Program and Family Guidance Association of Ethiopia Supported CBD Programs in Contraceptive Prevalence Rate, Sidama Zone, SNNPR

open access: yes, 2003
A comparative cross- sectional study was conducted in Sidama Zone, SNNPR to identify reasons for the difference in contraceptive prevalence rate between the Sidama Development Program (SDP) and Family Guidance Association of Ethiopia (FGAE) supported ...
Alano, Abraham
core  

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Contraceptives in chronic lymphocytic leukemia (CLL): a narrative review. [PDF]

open access: yesAnn Hematol
Al-Shibly R   +4 more
europepmc   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore   +16 more
wiley   +1 more source

Task-shifting through community health workers: factors influencing access and utilization of modern family planning methods in Ziniaré, Burkina Faso. [PDF]

open access: yesFront Reprod Health
Koinda F   +12 more
europepmc   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source

Hormonal Contraceptives and Migraine Frequency and Severity in Women: A Systematic Review and Meta-Analysis. [PDF]

open access: yesCureus
Alju SK   +11 more
europepmc   +1 more source

Reducing Exposure Before Birth: An Interrupted Time Series Study of Prenatal Exposure to Fetotoxic Medications Under Risk Management Plans in Canada

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Canada's 2009 risk management plan (RMP) framework has not been evaluated for prenatal exposure impact. Conversely, widely used drugs such as nonsteroidal anti‐inflammatory drugs (NSAIDs) lack RMPs. We assessed first‐trimester exposure to RMP‐regulated medications following regulatory interventions and to NSAIDs following safety publications.
Nahiyan Saiyara Khan   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy